First Ever Trial Shows Promise for 'Magic Mushrooms'

[DIGEST: Scientific American, Lancet Psychiatry, Huffington Post]

The first clinical trial to use psilocybin, the active compound in “magic mushrooms,” to treat major depression shows promise in a small but breakthrough study. Researchers from Imperial College London gave psilocybin to 12 people suffering from severe depression. One week after receiving an oral dose of the compound, each participant exhibited significant improvement in symptoms. The study further demonstrated psilocybin’s safety in a supervised setting.

Six men and six women suffering from chronic, treatment-resistant depression took two doses of psilocybin (10 mg and 25 mg) separated by one week. Each participant had experienced major depression for 17.8 years on average and none of them had responded to standard treatment, such as selective serotonin reuptake inhibitors (SSRIs) or electroconvulsive therapy. Three months later, five of the participants were in complete remission. If larger studies confirm these findings, medical professionals treating those who don’t respond to therapy or traditional medications may have a new and powerful tool.

(Credit: Source.)

The study did not have a control group, and the participants received psychological support before, during and after each session. The participants relaxed on a bed and listened to music through earphones during each dosing session. Researchers monitored blood pressure, heart rate, and the compound’s psychoactive effects. For the most part, according to the study, the participants went on their own “inner journey” without interruption or interference. None of the participants required medical intervention due to negative side-effects. Some reported experiencing mild anxiety or nausea. The psychedelic effects of the dosage peaked after two to three hours. Most remarkably, eight of the 12 participants met the criteria for remission from depression one week after the two treatments. Relative to baseline, five participants were in complete remission after three months and two others continued to show improvement.

The results are not without some caveats. The study might be biased, some note, because certain participants

To read more, please continue to page 2.

admitted taking psilocybin at least once before. Past experience with psilocybin and its effects might have increased suggestibility and expectancy in participants, thereby affecting the outcome. Further studies can address these problems through the inclusion of a control group or by conducting a double-blind study, in which any information that may influence the behavior of the tester or the subject is withheld until after the test.

“You cannot conclude from this trial that psilocybin is a treatment for depression because there could be other reasons people responded, including the psychotherapy treatment [that accompanied the experimental treatment] and expectancy biases which can be part of this placebo effect,” says Dr. Stephen Ross, director of the Psychedelic Research Group at NYU Langone Medical Center. Dr. Ross is conducting his own clinical trials on psilocybin’s effects on cancer-related depression.

Robin Carhart-Harris is a neuropsychopharmacologist at Imperial College London and one of the authors of the study. The study, he says, does not suggest that doctors should not use psilocybin as a last resort for their depressed patients. “That is pretty remarkable in the context of currently available treatments,” he said. “Our conclusion is more sober than that—we are simply saying that this is doable. We can give psilocybin to depressed patients, they can tolerate it, and it is safe. This gives us an initial impression of the effectiveness of the treatment.”

Robin Carhart-Harris (Credit: Source.)

However, previous studies have shown that psilocybin could be a viable treatment for anxiety, obsessive-compulsive behavior and addiction. Research suggests psilocybin is not an independent risk factor for mental health problems. Nevertheless, demonstrating the safety of psilocybin in a clinical setting was tricky. “Magic Mushrooms” are a Class A Illegal Drug in the United Kingdom. This is the harshest category, which also includes heroin and cocaine. The ethics committee that granted approval for the trial expressed concern that participants could experience delayed onset psychotic symptoms and requested a three-month follow-up for the volunteers. “Every interaction—applying for licenses, waiting for licenses, receiving the licenses, applying for contracts for drug manufacture, on and on—involved a delay of up to two months. It was enormously frustrating, and most of it was unnecessary,” says neuropsychopharmacologist David Nutt, the study’s main author. “The study result isn’t the remarkable part—it’s the fact that we did it at all.”

Depression is the “leading cause of disability worldwide,” according to the World Health Organization. Researchers looking for alternative treatments have turned to ketamine and ayahuasca, both of which have shown promise in clinical trials. “It’s worth noting that we have not developed any new treatments which are widely used since the 1970s for depression, despite the fact that this is the major public-health problem in the Western world and middle-income countries,” says Glyn Lewis, who studies psychiatric disorders at University College London. Psilocybin is a promising alternative, Lewis notes, because it appears to take effect after a single dose, whereas some current medications for depression must be taken daily.

“This study is simply asking: is this interesting enough to pursue further as a treatment for depression?” says Lewis. “My own judgment is that yes, it is.”

CNN video; Samuel Corum/Getty Images

With the world facing a viral pathogen with no vaccine or proven effective treatment, people are understandably on edge.

Hoping to give people a smile or a laugh, lawyer and fiscally conservative Republican—and Donald Trump adversary—George Conway decided to give folks the set up for an old joke with a new twist.

Keep reading... Show less
Chip Somodevilla/Getty Images

Even the most powerful office on the planet requires a level of humility and a willingness to admit when something goes wrong. President Donald Trump didn't get that memo.

Whether it's on Obama, the "fake news media," traitorous Republicans, the impeachment "hoax," or anything within even the most laborious reach, Trump can always find some person or entity on whom to pass the blame.

Keep reading... Show less
Fox Business

After less than a year on the job and with zero White House press briefings to her name, Stephanie Grisham will step down as White House press secretary, returning to her work with First Lady Melania Trump as her Chief of Staff.

Stephanie Grisham is the third White House Press Secretary to step down during the administration of President Donald Trump.

Keep reading... Show less
Shannon Finney/Getty Images

Across the country, states have instituted stay-at-home orders in an effort to curb the spread of the highly contagious virus that's upended daily life in the United States.

Late last month, Wisconsin Governor Tony Evers issued one of these orders, urging his constituents to only leave their houses for necessary errands, such as getting groceries or filling prescriptions.

There's just one problem: Wisconsin's elections are scheduled for April 7. In addition to the Presidential primaries, Wisconsinites will vote for judicial positions, school board seats, and thousands of other offices.

The Democratic and Republican National Committees took the case to the Supreme Court, with Democrats arguing that the deadline for mailing absentee ballots should be extended by a week, to April 13, in order to facilitate voting from home.

With a Wisconsin Supreme Court Seat up for grabs on Tuesday, Republicans predictably made the case for why as few people as possible should be permitted to vote. It was a continuation of Wisconsin GOP efforts to suppress the vote, which included rejecting a demand from Governor Evers to automatically mail an absentee ballot to every resident.

The Republican majority in United States Supreme Court sided with the RNC and the election in Wisconsin will carry on as scheduled. This is despite Wisconsin being unprepared for the surge in absentee ballot requests, which leapt from a typical 250,000 to over 1.2 million in reaction to the virus. Thousands of these voters won't even receive these ballots until after the election, thereby preventing them from exercising their right to vote.

Justice Ruth Bader Ginsburg wrote a blistering dissent to the majority's decision, saying:

"Either [voters] will have to brave the polls, endangering their own and others' safety. Or they will lose their right to vote, through no fault of their own. That is a matter of utmost importance — to the constitutional rights of Wisconsin's citizens, the integrity of the State's election process, and in this most extraordinary time, the health of the Nation."

She was flabbergasted that her more conservative colleagues didn't think a global pandemic and national crisis was enough to justify emergency policies ensuring Wisconsinites their right to vote:

"The Court's suggestion that the current situation is not 'substantially different' from 'an ordinary
election' boggles the mind...Now, under this Court's order, tens of thousands of absentee voters, unlikely to receive their ballots in time to cast them, will be left quite literally without a vote."

A majority of the Supreme Court may not have agreed with Ginsburg, but the court of public opinion was fully on her side.

The Republican efforts indicated to some that the party cares more about maintaining control than preserving lives.

Large crowds are already gathering in Wisconsin to vote.

In a bit of devastating irony, the Supreme Court voted remotely when making its decision.

For more information about the tried and true tactic of GOP voter suppression, check out Uncounted, available here.

JIM WATSON/AFP via Getty Images

Despite numerous cautions from medical experts—including those on his staff—President Donald Trump continues to tout hydroxychloroquine as a promising treatment for the virus that's brought daily life in the United States to a standstill.

The drug has undergone no clinical trials to scientifically test its efficacy on the virus, and the evidence on its behalf is anecdotal at best. One Fox News guest, Access Health International Chairman William Haseltine, called it a "quack cure."

Keep reading... Show less
Catherine Nance / Echoes Wire/Barcroft Media via Getty Images

President Donald Trump's personal lawyer, Rudy Giuliani, is back in the public eye after keeping a relatively low profile following the impeachment trial against his client.

Keep reading... Show less